Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2009

View Archived Issues

GLURP-MSP3 hybrid malaria vaccine found safe and immunogenic in phase I trial

Phase I data links antiangiogenic effects of Ang-(1-7) to reduced PIGF levels in solid tumors

Phase II data show thromboprophylactic effects of TAK-442 after total knee replacement

Preliminary phase I data disclosed on MDX-1342 in relapsed/refractory CLL

ABT-869/paclitaxel shows preliminary antitumor activity in patients with breast cancer

Eisai to acquire AkaRx and thrombocytopenia therapeutic AKR-501

Labopharm initiates European regulatory approval process for tramadol/acetaminophen

ThromboGenics completes enrollment in second phase III trial of microplasmin

Synta initiates phase II trial of STA-9090 in non-small cell lung cancer

Keryx begins phase III registration trial of perifosine in multiple myeloma

Naurex initiates phase I trial of NMDA modulator GLYX-13 for depression

Anadys reports 4-week results of phase II trial of ANA-598 in hepatitis C

Durect reports encouraging data from phase IIb trial of Posidur in postsurgical pain

Ariad completes enrollment in phase III trial of ridaforolimus in metastatic sarcoma

Arno Therapeutics enrolls first patient in phase II trial of AR-67 in glioblastoma multiforme

Ligand and Neurogen amend merger agreement

Clinuvel reports preliminary phase III results of afamelanotide in polymorphic light eruption

Almirall and Forest Laboratories expand respiratory collaboration with LAS-100977

FDA's advisory committee votes on benefit-risk of Crestor in JUPITER study

Hiroshima University identifies novel compounds with oncolytic and antibacterial activity

Novel MST1R and HGFR kinase inhibitors identified by OSI as oncolytics

CB1 antagonists for the treatment of obesity described by sanofi-aventis

CSIRO claims novel antimicrobial agents for bacterial and fungal infections

NOS-2 inhibitors disclosed by Brazilian scientists for the treatment of inflammatory disorders

Abbott describes histamine receptor ligands for the treatment of asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...